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Abstract:  IL-6 plays a crucial role in the development of acute 
phase response. One of the important regulators of 
IL-6-activated APR is peroxisome proliferator activated 
receptor alpha (PPARα). Currently, there is a growing interest 
in determining the role of PPARα in regulating the gene 
expression of acute phase proteins. However,   studies into the 
molecular mechanisms and signaling pathways in mediating 
the effects of IL-6 on the expression of PPARα are extremely 
limited. In this study, we determined that MAPK pathways, p38 
and ERK but not JNK were involved in the down regulation of 
PPARα by IL-6 via the activation of SHP2. ERK may exert its 
effect by activating the downstream transcription factor, 
C/EBPα and -β. By contrast, ATF2 was not activated by p38 
suggesting that p38 may produce its effect via other 
transcription factors. In this study, we also identified that, p38 
and ERK pathways were involved in the DNA binding of 
STAT1 and -3, and were responsible for  mediating the 
inhibitory action of STAT1 and -3 on PPARα promoter 
activity. Accordingly, this study has unravelled novel pathways 
by which IL-6 inhibits PPARα gene transcription, involving the 
modulation of p38 and ERK-C/EBP by activating the binding 
of STAT1 and -3 to STAT binding site on PPARα promoter. 
These findings represent a new model of IL-6-induced 
suppression of PPARα expression  by the  induction of STAT1 
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and STAT3 phosphorylation and the subsequent 
down-regulation of PPARα mRNA expression. 
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1.  Introduction 
 
he acute phase response (APR) is the immediate 
inflammatory reactions mediated by cytokines in response 
tissue injury, infection and trauma [1], including remarkable 
changes in the concentrations of many plasma proteins, known 
as the acute phase proteins (APPs) [2]. One of the most 
important cytokines responsible in the activation of APR is 
IL-6. This pro-inflammatory cytokine regulates hepatocyte 
APPs genes via the activation of certain signal transduction 
pathways, which in turn, stimulate transcription factors, such as 
STATs, NFκB and C/EBP [3]-[8].  
     Recently, there is accumulating evidence that a member of 
ligand-activated nuclear hormone receptors, PPARα may play 
an important role in the development of APR. The expression 
of PPARα was found to be decreased in liver treated with 
cytokines [9]-[11]. Indeed, we recently, demonstrated that 
cytokines produced an inhibitory effect on PPARα gene 
expression [12]. Interestingly, Gervois [4] showed the 
suppression of APPs gene expression was mediated by PPARα 
following the IL-6-induced APR in mice.  
     In light of the recent evidence that PPARα gene expression 
is regulated during IL-6-induced APR, which in turn regulates 
the expression of several key APPs, it is crucial that a detailed 
understanding of the molecular mechanisms of the signaling 
pathways underlying the response is studied. Recently, we 
reported that IL-6 decreased the PPARα gene expression at the 
transcriptional level via the action of C/EBP members [12]. In 
this study, we further explore the mechanisms involved in the 
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modulation of PPARα gene expression and binding activity by 
IL-6-triggered signal transduction pathways using human 
hepatocarcinoma HepG2 cell line as a model system. 
 
2.   Materials and methods 
 
2.1. Materials 
 
     The recombinant human IL-6 was obtained from National 
Institute for Biological Standards and Control, UK and the 
human HepG2 cell line was purchased from American Type 
Culture Collection (ATCC). All the cell culture reagents were 
purchased from Gibco/BRL. Rabbit polyclonal antibodies were 
purchased from Cell Signaling Technology (Beverly, MA, 
USA). Pharmacological inhibitors, NSC87877 was purchased 
from Tocris Bioscience (St. Louis, MO, USA), SB203580, 
U0126 and SP600125 were obtained from Calbiochem (Pacific 
Center Court San Diego, CA, USA). 
 
2.2. Cell culture and IL-6 treatment 
 
     HepG2 cell lines were cultured in MEM supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (HI-FBS), 100 
U/ml penicillin and 100 g/ml streptomycin. Cells were 
maintained at 37˚C in a humidified atmosphere with 5% (v/v) 
CO2. Prior to treatment with 1000 U/ml of IL-6 or various 
inhibitors, the cells were pre-incubated in reduced 
concentration of HI-FBS (0.5%) for 4 hr [13].  
 
2.3. Real-time RT-PCR 
 
     Total cellular RNA was isolated from HepG2 cell line using 
Tri-Reagent LS (Molecular Research Center) according to the 
manufacturer’s instruction. Real-time RT-PCR was performed 
using iScript One-Step RT-PCR Kit with SYBR Green 
(Bio-Rad) [12]. The quantity of PPARα mRNA was 
normalized against the housekeeping gene, β-actin, which acted 
as the internal control to determine the relative PPARα mRNA 
expression. 
 
2.4. SDS-PAGE and Western blot analysis 
 
     Total cellular protein was isolated using NE-PER® Nuclear 
and Cytoplasmic Extraction Reagents (Pierce) following 
manufacturer’s instructions. The cytoplasmic extracts were 
prepared from the control and treated cells. Total cellular 
proteins were then size-fractionated on SDS-PAGE and 
transferred to a polyvinylidene difluoride membrane 
(Milipore). The blotted membranes were incubated with 
blocking solution [1XPBS containing 5% (w/v) skimmed milk 
powder and 0.1% (v/v) Tween-20] for 1 hr at room temperature 
with shaking. Blocking solution was removed by washing the 
membrane three times for 10 min each, in washing solution 
[1XPBS and 0.1% (v/v) Tween-20] and the membrane was 
incubated with individual primary antibodies against the 
component of signal transduction pathways which was diluted 
1/1000 in 1XPBS containing 1% (w/v) skimmed milk powder 
and 0.1% (v/v) Tween-20, for 1 hr at room temperature, with 
shaking. The membrane was then washed and immersed in 
secondary antibody (peroxidase-conjugated goat anti-rabbit 
IgG) diluted 1/2000 in 1XPBS containing 1% (w/v) skimmed 
milk powder and 0.1% (v/v) Tween-20. Detection of membrane 
bound antigen-antibody complexes was carried out as 
described in the instructions supplied with the ECL kit (GE 
Healthcare) and Fuji Medical X-ray film. 
 
2.5. Electrophoretic mobility shift assay (EMSA) and antibody 
supershift assay 
      
     Nuclear extracts used in EMSAs were extracted using 
NE-PER® Nuclear and Cytoplasmic Extraction Reagents 
(Pierce). The sequences of the oligonucleotides containing 
STAT binding site (-612 to -604) [12] were as follows: 
5’-AGAATTCTTCCTCCAAGAGTTA-3’ and 
5’-TAACTCTTGGAGGAAGAATTCT-3’. The 
oligonucleotides were labeled using biotin 3’-End DNA 
Labeling kit (Pierce) according to manufacturer’s instructions. 
For binding reactions, 20 g of nuclear extracts were mixed 
together with labeled oligonucleotides using LightShift® 
Chemiluminescent EMSA kit (Pierce) according to 
manufacturer’s instructions. DNA-protein complexes were 
then resolved by electrophoresis using 6% (w/v) 
non-denaturing polyacrylamide gels (29:1, 
acrylamide:bisacrylamide). DNA-protein complexes were 
transferred to nylon membrane (Hybond N+) and subsequently, 
detection of the biotin-labeled DNA on the membrane was 
carried out using Fuji Medical X-ray film. For antibody 
super-shift assays, 1 µg of STAT1 or STAT3 antibody (Cell 
Signaling Technology) was mixed with the binding reactions 
and the mixture was incubated on ice for 20 min followed by 
room temperature for another 20 min before the labeled 
oligonucleotides were added. 
 
2.6. Transient transfection assay 
      
     The construction of the human PPARα promoter -765/+34 
in pGL3-Basic Vector was described previously [12]. The 
HepG2 cells were transfected with the plasmids using 
Lipofectin transfection reagent (Invitrogen® Life 
Technologies) according to manufacturer’s instruction with 
slight modification as previously described [12], [14]. Cells 
were re-plated 12 hr before transfection at a density of 9x105 
cells in 2 ml of fresh culture medium in a 6-well plastic dish. 
The cells were transfected with 2 g of wild type PPARα 
promoter luciferase construct or the STATmut PPARα 
promoter luciferase construct and 0.5 mg tymidine 
kinase/Renilla (pRL-TK) vector as the control for transfection 
efficiency. Luciferase activity was measured by using the 
Dual-Glo luciferase assay system (Promega). 
 
2.7. Statistical analysis 
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Figure 1. The effects of various inhibitors on IL-6-mediated suppression of PPARα mRNA. HepG2 cells were cultured in 0.5% (v/v) HI-FCS 
for 4 hr and then pre-treated with (A) SB203580 (B) U0126 (C) SP600125 and (D) NSC878777 for 2 hr prior to treatment with 1000 U/ml of 
IL-6 for 24 h. Total cellular RNA was then isolated and subjected to Quantitative Real-Time PCR. Assigning the signals for PPAR α/β-actin 
ratio in unstimulated cells as 100%, the expression of PPARα for each dose response treatment was relative to this control value. Effect of 
inhibitors on the IL-6 treated PPARα mRNA suppression was statistically analyzed by one-way analysis of variation (ANOVA). Statistical 
significance (* P<0.05, ** P<0.01 and *** P<0.001) is indicated above bar.  
     Statistical analysis was determined using one-way analysis 
of variation (ANOVA) or paired t-test available in GraphPad 
Prism® Version 3.02 software. Statistical significance was 
considered significant (p<0.05), very significant (p<0.01) or 
highly significant (p<0.001). 
 
3.  Results 
 
3.1.  IL-6-inhibitory effects on PPARα mRNA expression are 
mediated by AMPK pathways  
 
     Our previous study showed that IL-6 down-regulated the 
expression of PPARα at the levels of mRNA, protein content 
and binding activity [12]. In order to determine the role of 
MAPK pathways in mediating the inhibitory action of IL-6 on 
PPARα mRNA expression, various inhibitors were used. The 
cells were pre-treated individually either with NSC87877, an 
inhibitor against tyrosine phosphatase 2 (SHP2), an upstream 
component of MAPK pathway that is linked to the IL-6 
signaling via gp130 [15], [16] as well as SB203580, U0126 or 
SP600125, the specific inhibitors of p38, MEK, and 
MKK4/7-JNK, respectively. As shown in Fig. 1D, NSC87877 
attenuated the inhibitory effect of IL-6 on PPARα mRNA 
expression in a dose-dependent manner with maximal increase 
of 20% as compared to IL-6 treatment alone achieved at 40 µM. 
Figure 1, panel A-C, showed that SB203580 and U0126 
inhibited the IL-6-induced suppressive effect on PPARα 
mRNA levels with the highest inhibitory effect at 20 µM and 40 
µM, respectively. By contrast, no significant attenuation effect 
was observed when SP600125 was used. These results 
suggested that IL-6 exerted its inhibitory effect on PPARα 
mRNA expression in HepG2 cells through the activation p38 
and ERK, but, not JNK pathways. 
 
3.2. IL-6 activates the components of p38-ATF2 and 
ERK-C/EBP signal transduction pathways in HepG2 cells 
 
     The activation of the key components of MAPK pathways 
by IL-6 in HepG2 cells was investigated using Western blot 
analysis. Fig. 2A showed that treatment of HepG2 cells over a 
period of 120 min produced a marked increase in the levels of 
phosphorylation of Tyr180/182 p38 and Tyr71 ATF2 within 30-45 
min but not total p38 and ATF2. A time-dependent increase in 
the levels of phosphorylated ERK p44/p42 and an increase in 
Ser21 C/EBPα, Thr222/226 C/EBPα and Thr235 C/EBPβ (Figure 
2B) were also observed. In all cases, the levels of 
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Figure 2. Time-dependent effect of IL-6 on the components of MAPK activity. Confluent HepG2 cells were treated with 1000 U/ml IL-6. 
The cytoplasmic extract were prepared and subjected to Western blotting using specific antibodies for phosphorylated form of (A) p38 and 
ATF2 (B) ERK and C/EBP. After stripping these membranes, each membrane was individually re-blotted with specific antibodies for p38, 
ATF2, ERK and C/EBP. Fig. 2C-D Cells were pre-treated with various concentrations of inhibitors for 2 h, followed by stimulation with 1000 
U/ml of IL-6 for the prerequisite time. Cytoplasmic extracts were prepared and subjected to Western blotting using various antibodies as 
described. 
 
phosphorylated proteins were increased after 15 min for ERK 
followed by C/EBPα and C/EBPβ after 45 min.  
     In order to corroborate that p38-ATF2 and ERK-C/EBP 
pathways were indeed activated in response to IL-6 treatment, 
the cells were pre-incubated with pharmacological inhibitors 
for 2 hr followed by IL-6 treatment for a requisite time. As 
shown in Figure 2C, the induction of phosphorylated p38 by 
IL-6 was inhibited by NSC87877. Similar attenuation affect 
was also produced by SB203580 on the phosphorylation level 
of p38 with the highest level produced at 20 µM. By contrast, 
similar concentration of SB203580 did not produce a 
significant inhibition on the phosphorylation of ATF2 (Figure 
2C). In delineating the ERK-C/EBP pathway, it was 
demonstrated that NSC87877 abolished the phosphorylation 
level of p44/42 of ERK at 40 µM, corresponding to the 
attenuation effect of IL-6 suppression of PPARα mRNA 
expression. U0126 at concentration of 40 µM markedly 
inhibited the phosphorylation of C/EBPα and C/EBPβ (Figure 
2D). Thus, these results clearly suggest that two components of 
MAPK pathway, p38, and, ERK via the activation of C/EBPα 
and C/EBPβ, may play an important role in mediating the 
inhibitory effect of IL-6 on PPARα gene expression. 
 
3.3. p38 and ERK activates STAT-1 and-3 
      
     In order to investigate p38 and ERK pathways were 
involved in the activation of STAT; inhibitors were used to 
block the STAT phosphorylation. It was found that, an increase 
in the concentration of SB203580 and U0126 partially inhibited 
the tyrosine phosphorylation residues of STAT1 and STAT3 
(Figure 3). However, the level of attenuation of the serine 
phosphorylation by both inhibitors was not significant 
suggesting that p38 and ERK activated STAT1 and -3 via the 
phosphorylation of tyrosine residue. 
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3.4. p38 and ERK pathways are involved in IL-6-induced 
suppression on PPARα promoter activity 
 
     We previously demonstrated that the human PPARα 
promoter construct carrying the region from -765 to +34 
displayed an approximately 50% decrease in luciferase activity 
in HepG2 cells-treated with IL-6 [12]. Because IL-6 decreased 
the PPARα mRNA levels via p38 and ERK pathways, we then 
investigated the role of similar pathways in modulating the 
PPARα promoter activity. As shown in Fig. 4A, NSC87877 
produced the highest inhibition, followed by U0126 and 
SB203580. This pattern of attenuation activity also indicates 
that the inhibitors used at the upstream cascade blocked the 
IL-6  suppression  on  the  PPARα  promoter  activity      more  
 
 
 
Figure 3. The effects of p38 and ERK inhibitors on the 
phosphorylation of STAT1 and -3. Pre-treatments of cells with 
SB203580 and U0126 were followed by incubation with IL-6 for 
requisite time to determine the levels of phosphorylated STAT1 and 
-3. 
 
 
 
effectively than the inhibitor used at the downstream. As 
expected, the SP600125 (JNK inhibitor) did not show a 
significant inhibition of transcription of the promoter activity 
(Figure 4A).  
 
3.5. STAT1 and -3 are responsible in mediating the 
IL-6-induced suppression of PPARα expression through p38 
and ERK pathways 
  
     The scanning of the PPARα promoter using MatInspector 
[17] revealed the presence of the potential binding site for 
STAT transcription factor located between nucleotides -612 
and -604. We, next, examined the interaction of nuclear 
extracts, prepared from HepG2 cells treated with IL-6 over the 
period of 120 min, with the STAT binding site. EMSA showed 
three major DNA-protein complexes designated as C1-C3 were 
present in untreated cells, with IL-6-treated nuclear extracts 
produced a significant induction in the DNA-protein complexes 
C2 and C3 at 15 min and 30 min (Figure 4B). The specificity of 
complexes C2 and C3 was confirmed when these complexes 
were significantly competed out using 400X of unlabeled 
STAT oligonucleotides (Figure 4C). Complex C1 may 
represent the non-specific interaction as the complex was not 
competed out by unlabeled oligonucleotides. Antibody 
supershift experiment showed that complexes C2 and C3 
contained STAT1 and -3 (data not shown). 
     Pre-treatment of cells with SB203580 and U0126 markedly 
inhibited STAT binding activity, thereby decreasing the 
formation of complexes C2 and C3 (Figure 4C). In contrast, 
SP600125 showed no effect towards the formation of the 
complexes C2 and C3. Thus, it is conceivable that these 
observations indicate that the formation of complexes C2 and 
C3 were regulated via the activation of p38 and ERK. 
 
4.  Discussion 
 
     PPARα is of crucial importance in many pathological 
conditions such as in the regulation of APPs [3, 4, 18-20]. Due 
to the critical role of PPARα in regulating APPs, the 
mechanisms involved in the modulation of PPARα suppression 
by IL-6 is clearly important. In this current study, we 
demonstrated for the first time a crucial role of SHP2 associated 
p38 and ERK but not JNK in mediating the inhibitory effect of 
IL-6 on PPARα expression and promoter activity in HepG2 
cells.  
     An increasing body of evidence supports the role of SHP2 in 
inducing the phosphorylation of the components of MAPK 
[15]. It was demonstrated that phosphorylation of the different 
members of MAPK is regulated by SHP2-binding site Tyr759 of 
gp130 at the membrane cell [21]. Interestingly, Olsnes [22] also 
found only two components of MAPK (ERK and p38) but not 
JNK are capable of producing the cellular effects by the 
mediator. For example, in sclerosant-treated monocytes, 
phosphorylated ERK and p38 alone are responsible in 
regulating the secretion of IL-6 and TNF-α. 
     Dong [23] elucidated that C/EBP signaling pathway was 
activated at the downstream level by IL-6 which contributed to 
increased expression of plasminogen activator inhibitor-1 
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Figure 4. The effects of various inhibitors on the IL-6-mediated suppression of PPARα promoter activity in HepG2 cells. (A) HepG2 cells 
were transfected with luciferase-reporter construct containing the promoter of PPARα gene (-765/+34) in the absence and presence of IL-6. 
The transient transfected cells were then pre-treated with NSC87877, SB203580, U0126 and SP600125 for 2 hr prior to treatment with 1000 
U/ml of IL-6 for 24 hr. Relative induction (%) of the promoter constructs activities in IL-6 treated cells inhibitors and without treatment of 
individual inhibitors, as compared to untreated cells (control) which has been assigned as 100%. (B) DNA-binding proteins of nuclear 
extracts to the STAT binding site of PPARα promoter in time-course upon IL-6 treatment. (C) HepG2 cells were either untreated or 
pre-treated with SB203580 (SB), U0126 (U) and SP600125 (SP), respectively for 2 hr before incubation in the absence or presence of 1000 
U/ml of IL-6 (IL6) for 30min. Nuclear extracts were then isolated and 20 µg of nuclear extract were subjected to EMSA using biotin-labeled 
STAT (-612/-604) oligonucleotides. C represents patterns of DNA-protein complexes (C1, C2, and C3) detected, indicated by labeled 
arrows. UNT (untreated control) represents cells treated in the absence of IL-6, CP (cold probe) represents competition assay using 400-fold 
molar excess of unlabelled STAT oligonucleotide and FP (free probe) represents biotin-labelled STAT oligonucleotide alone. 
 
(PAI-1) in HepG2 cells and primary mouse hepatocytes. 
Indeed, the finding that C/EBP proteins are located at the 
downstream of ERK upon stimulation of IL-6 was supported 
elsewhere. U0126 was found to block the phosphorylation of 
C/EBP by inhibiting the phosphorylation of ERK1/2. In 
addition, Ross [24] reported that the inhibition of 
granulopoiesis was due to the inhibition of C/EBP which was 
mediated by ERK1/2 pathway. In fact, we recently 
demonstrated the role of C/EBP in down-regulating the 
promoter and binding activity of PPARα in IL-6-treated HepG2 
cell line [12]. 
     Interestingly, although it has been reported that ATF2 was 
activated via p38 pathway upon stimulation with mediators 
such as insulin-like growth factor-1 [25], [26], this study did 
not support that finding. Therefore, it is tempting to speculate 
that phosphorylation of ATF2 by IL-6 in HepG2 cells may be 
mediated by other IL-6-activated pathways. In fact, ATF2 is 
known to be activated via pathways other than MAPK such as a 
novel Polo-like kinase 3 (Plk3) pathways in human corneal 
epithelial (HCE) cells [27]. 
     A potential role of STAT as the downstream effector of p38 
and ERK in binding and regulating the PPARα promoter 
activity in IL-6-treated liver cells was observed in this study. 
Previous studies also showed the role of IL-6-induced 
phosphorylation of STAT via the activation of p38 in 
modulating other promoter activity such as haptoglobin [28]. It 
was also reported that U0126 inhibited the phosphorylation of 
STAT3 in a series of end stage plasma B cell upon IL-6 
treatment suggesting the role of ERK in activating STAT [29]. 
Therefore, STAT binding site may be predominant responsive 
element for IL-6 signaling and the binding of STAT protein to 
their DNA motif presence on the human PPAR  promoter may 
have caused the suppression of PPARα upon IL-6 treatment. 
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From the previous study, the activation of STAT1 and -3 were 
discovered when HepG2 cells were treated with IL-6.  
     Accumulating evidence reported that an increase in activity 
and level of STAT was found to down-regulate the expression 
of PPARα during the acute phase response [30], [31] and 
instead of widely reported JAK pathway, other pathways may 
also played a critical role in mediating the cellular IL-6-effects 
via activating STAT. Indeed, EMSA demonstrated that the 
specific binding site of STAT (-612/-604) sequence in PPARα 
promoter was crucial for IL-6 suppression of PPARα synthesis 
and strongly suggested that MAPK pathways, p38 and ERK, 
were involved in the activation of STAT1 and -3. 
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